XIAOMI-W (01810.HK) rose 0.29% to HKD 27.660. Unitree launched the 22-DoF Dex5-S dexterous hand; GENISOM AI completed a B round.
September 22, 2026, SKYFAME REALTY(00059.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 51.07 million, decreased by 1.18% YoY
On 22 September 2026, GENFLEET-B (02595.HK) announced that its clinical program of GFH375 combined with cetuximab was placed on the proposed BTD list on 18 September 2026 for KRAS G12D mutant metastatic colorectal cancer.
On 22 September 2026, ZYBANK (01216.HK) announced completion of its 2026 undated capital bonds (first tranche) with an issue size of RMB 10 billion at a 1.92% coupon for the first 5 years, used to replenish additional tier 1 capital.
On 21 September 2026, HENGRUI PHARMA (01276.HK) announced NMPA approval for clinical trials of HRS-4729 injection in chronic kidney disease and HRS-1596 tablets for weight management and type 2 diabetes, with cumulative R&D investment of about RMB 106 million.
On 21 September 2026, CF PHARMTECH (02652.HK) announced that its Phase I clinical trial of ICF004, an inhalation powder for interstitial lung disease, has completed enrolment and dosing of its first healthy subject, with further studies planned.
On 21 September 2026, EMINENCE CAP GP (00770.HK) announced it had acquired 26,200,000 Canopy Skyfire Group (08245.HK) shares for HK$ 4,822,400, about 9.05% of its capital, constituting a major transaction that breached the 20% limit under Rule 21.04(3)(b).
On 21 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary received NMPA approval for clinical trials of SHR-4595 for injection in patients with advanced solid tumours, with cumulative R&D investment of about RMB 16.4 million.
On 21 September 2026, SICHUAN EN INV (01713.HK) announced EPC general contracting and construction supervision contracts for the 2025 rural power grid project, valued at RMB 1.332 billion and RMB 27.86 million, constituting connected transactions.
On 22 September 2026, EVEREST GOLD (01815.HK) announced the issue of 277 million new shares at HKD 1.60 each to six subscribers, raising gross proceeds of about HKD 443.2 million, with roughly 90% of net proceeds for its gold bar business.
On 21 September 2026, LEADS BIOLABS-B (09887.HK) said its pivotal LBL-024 EP-NEC trial was selected as an ESMO 2026 late-breaking abstract.
On 21 September 2026, GREEN BROAD (01253.HK) will issue 595,087,758 swap shares at HKD 0.26 each to settle HKD 154,722,817 of debt owed to Greenland Financial.
On 21 September 2026, LIGENT (09856.HK) priced its global offering of 172,014,700 shares at HKD 32.96 each; the HK public offer was 35.16 times subscribed.
On 21 September 2026, SCHOLAR EDU (01769.HK) said its trustee bought 135,000 shares on market under the share award scheme at an average of HKD 0.84.
On 21 September 2026, UNITY ENT (02195.HK) reported interim revenue of about HKD 114.1 million, down 4.2%, and a loss of about HKD 13.0 million.
On 21 September 2026, GUOFUHEE (02582.HK) posted interim revenue of RMB 104,036,000, down 4.5%, and a loss of RMB 122,478,000.
